Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05164172 · ClinicalTrials.gov registry record · Phase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
A Phase 3 study of Migraine, sponsored by H. Lundbeck A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05164172: Recruiting Phase 3 study of Migraine, sponsored by H. Lundbeck A/S.
NCT05164172 is a Phase 3 study of Migraine that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 600 participants, above the 352-participant average among 102 other Migraine trials with a reported enrollment target (70% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05164172, a Phase 3 study of Migraine, is actively recruiting participants, sponsored by H. Lundbeck A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Conditions Studied
Interventions
- DRUG Eptinezumab
Study Locations (20)
Florida
- NW FL Clinical Research Group, LLC - Gulf Breeze
- AGA Clinical Trials - Hialeah
- Axcess Medical Research - Loxahatchee Groves
- University of South Florida - Tampa
Michigan
- Michigan Head Pain and Neurological Institute - Ann Arbor
- Michigan State University - Department of Neurology - East Lansing
- Helen Devos Childrens' Hospital - PIN - Grand Rapids
Connecticut
- Yale University School of Medicine - New Haven
- Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford
New York
- Dent Neurosciences Research Center Incorporated - Amherst
- True North Neurology - Commack
Ohio
- Childrens Hospital Medical Center of Akron - Akron
- Cincinnati Children's Hospital Medical Center - PIN - Cincinnati
Kentucky
- University of Kentucky - Lexington
Maryland
- University of Maryland School of Medicine - Baltimore
North Carolina
- OnSite Clinical Solutions, LLC - Randolph Rd - Charlotte - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 3 |
What NCT05164172 shows while recruiting
NCT05164172 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 352-participant average among 102 other Migraine trials with a reported enrollment target (70% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Eptinezumab is the first listed.
NCT05164172 names 20 study sites across 12 states, led by Florida, Michigan, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05164172 about?
NCT05164172 is a clinical study titled "A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine". The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
What is the current status of trial NCT05164172?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2021-12-01. Estimated completion is 2028-04-30.
What conditions does trial NCT05164172 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05164172?
The interventions under investigation include: Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT05164172?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05164172 being conducted?
This trial has 20 study locations across Connecticut, Florida, Kentucky, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05164172's enrollment target sits among peer trials
600 17th of 102 higher than 86 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
-
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI